All In Biotech

Drug Trial Radar · NCT06908993

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

A Randomized Controlled Trial of Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 133 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

133

Planned (sponsor's estimate)

Start

Dec 9, 2025

Primary completion

Mar 15, 2028

Study completion Jul 15, 2028

Sponsor

Lead sponsor
Intergroupe Francophone de Cancerologie ThoraciqueAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The hypothesize is that tepotinib is more effective than the investigator's choice of treatment in patients with MET-mutated NSCLC who have progressed after at least one first-line treatment. The main benefit concerns patient access to tepotinib. There is currently no access to a new-generation MET TKI in France for METex14 patients, due to lack of comparative data. There are no phase III RCTs underway anywhere in the world. This study is the only opportunity, perhaps the last, to generate comparative data which, if positive, will enable the drug to be reimbursed. With this in mind, the methodology of this study was discussed with the HAS on several occasions beforehand, to ensure that it met their expectations. With a response rate of around 50% and a median progression-free survival of 11 months in previously-treated subjects based on clinical trials data, tepotinib is a key drug for METex14 NSCLC patients, who are generally elderly and frail, and for whom therapeutic options are limited. The investigators expect to observe a benefit for patients treated with tepotinib compared to the control arm in terms of PFS, quality of life, objective response rate and duration of response. The overall survival benefit may be compromised by allowing patients in the control arm to cross over to tepotinib once they have progressed. However, the investigators have decided to maintain this crossover and consequently use PFS as the primary endpoint, as there is no clinical equipoise regarding the efficacy of tepotinib in METex14 NSCLC patients. The EMA has already approved tepotinib based on efficacy and safety data from clinical trials, and patients and investigators already consider this treatment as an important therapeutic option. Indeed, both ESMO and ASCO guidelines recommend the use of MET TKIs in these patients. In France, although neither tepotinib nor capmatinib are available, crizotinib, a multi-target TKI also active on MET, can be used off-label. If cross-over to tepotinib was not allowed in this trial, most patients would still benefit from cross-over to a MET TKI by receiving off-label crizotinib, which would in any case lead to a misinterpretation of the OS data. Therefore, the investigators believe it is preferable to control for cross-over and expose progressive patients in the control arm to tepotinib and use PFS as the primary endpoint. Toxicity of MET TKIs is considered as manageable. In the VISION trial, of 313 patients treated with tepotinib (median age: 72 years), 109 (34.8%) experienced grade ≥3 treatment-related adverse events, leading to discontinuation in 46 patients (14.7%). Rates of adverse events (AE) were broadly consistent irrespective of prior therapies. Edema, the most common adverse event of clinical interest (AECI), was reported in 67.1% (grade ≥ 3, 11.2%). Median time to first edema onset was 7.9 weeks (range: 0.1-58.3). Edema was manageable with supportive measures, dose reduction (18.8%), and/or treatment interruption (23.1%), and rarely prompted discontinuation (4.3%). Other AECIs were also manageable and predominantly mild/moderate: hypoalbuminemia, 23.6% (grade ≥ 3, 3.5%); creatinine increase, 22.0% (grade ≥ 3, 1.0%); nausea, 23.3% (grade ≥ 3, 0.6%), diarrhea, 22.4% (grade ≥ 3, 0.3%), decreased appetite (grade ≥ 3, 0.3%), and ALT increase, 14.1% (grade ≥ 3, 2.2%). GI AEs typically occurred early and resolved in the first weeks10,13. Given the efficacy of tepotinib, the manageable safety profile, and the oral administration of tepotinib, the investigators anticipate that treatment with tepotinib will be associated with improved quality of life. Treatments offered in the control group correspond to standard treatments for advanced NSCLC in second line or beyond. In terms of prior lines of treatment, the eligibility criteria of the trial are aligned with the EMA label of tepotinib: "indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to MET gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy". The investigators have not included platinum-based chemotherapy as a treatment option in the control arm, considering that patients who are eligible to platinum-based chemotherapy should have received this regimen in first-line, as per ESMO guidelines14. Given the low efficacy of immunotherapy in patients with oncogene addiction, it is unlikely that some patients would receive immunotherapy alone as first-line treatment. Thus, the absence of platinum-based chemotherapy as a treatment choice in the control arm seems reasonable and will reduce the heterogeneity of this arm.

Conditions

  • Advanced Non Small Cell Lung Cancer
  • MET Exon 14 Mutation

Interventions

  • TepotinibDrug

    Tepotinib will be given orally once daily at the dose of 500mg of tepotinib hydrochloride hydrate.

  • Pemetrexed (Alimta)Drug

    500 mg/m² every 3 weeks

  • VinorelbineDrug

    25-30 mg/m² D1, D8, every 3 weeks

  • Gemcitabine aloneDrug

    1250 mg/m² D1, D8, every 3 weeks

  • DocetaxelDrug

    75 mg/m² every 3 weeks

  • PaclitaxelDrug

    90 mg/m² D1, D8, D15 every 4 weeks If bevacizumab added: 10 mg/kg D1, D15 every 4 weeks

  • PembrolizumabDrug

    200 mg every 3 weeks

  • NivolumabDrug

    240 mg every 2 weeks

  • AtezolizumabDrug

    1200 mg every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: About 36 months

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Besançon - CHU

    Besançon, France · Recruiting

  • Bordeaux - Institut Bergonie

    Bordeaux, France · Recruiting

  • Brest - CHU

    Brest, France · Recruiting

  • Caen - CRLCC

    Caen, France · Recruiting

  • Centre Hospitalier Intercommunal de Créteil

    Créteil, France · Recruiting

  • Dijon - Centre Georges-François Leclerc

    Dijon, France · Recruiting

  • Grenoble - CHU

    Grenoble, France · Recruiting

  • CHD Vendée

    La Roche-sur-Yon, France · Recruiting

  • Le Mans - CHG

    Le Mans, France · Recruiting

  • CHRU de Lille

    Lille, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Institut Paoli Calmette

    Marseille, France · Recruiting

  • Marseille - APHM

    Marseille, France · Recruiting

  • Montpellier - CHU

    Montpellier, France · Recruiting

  • Centre Antoine Lacassagne

    Nice, France · Recruiting

  • AP-HP Hôpital Cochin

    Paris, France · Recruiting

  • AP-HP Hôpital Tenon

    Paris, France · Recruiting

  • Paris - APHP Bichat

    Paris, France · Recruiting

  • Centre Hospitalier Général - Pau

    Pau, France · Recruiting

  • Bordeaux - CHU

    Pessac, France · Recruiting

  • Institut de Cancérologie de l'Ouest - René Gauducheau

    Saint-Herblain, France · Recruiting

  • Sens - CH

    Sens, France · Recruiting

  • Strasbourg - NHC

    Strasbourg, France · Recruiting

  • Toulon - CHI

    Toulon, France · Recruiting

  • CHU Toulouse

    Toulouse, France · Recruiting

  • CHRU de Tours

    Tours, France · Recruiting

  • CH de Valence

    Valence, France · Recruiting

  • Nancy - CHU

    Vandœuvre-lès-Nancy, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.